Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Cellular Goods highlights recent developments and milestones for its 'Look Better' skincare range

Cellular Goods PLC

Cellular Goods PLC (LSE:CBX) chairman and interim CEO Darcy Taylor takes Proactive's Stephen Gunnion through the latest developments in the company's wellness business. Taylor highlighted the recent launch of their wellness division in several European countries, including France, Germany, Austria, Italy, Portugal, and Spain. This expansion aligns with their strategy to enter cannabigerol (CBG) friendly markets with high consumer demand and promising return on investment. The company's aim is to increase accessibility to its 'Look Better' skin range and enhance geographic distribution. Taylor also mentioned Cellular Goods' successful launch on the Sephora UK marketplace back in May, emphasizing the significance of the company's participation in promotional campaigns to increase product awareness. As the first CBD skincare brand in Sephora's offerings, these campaigns have been pivotal in expanding their customer base and leveraging their brand. Additionally, Taylor discussed the inclusion of their rejuvenating face serum in Jamie Greenberg's highly-anticipated 'swag bag', a significant endorsement from the renowned makeup artist. This has helped boost their presence and customer traction in the US market. Another strategic partnership highlighted is with Chill.com, a wellness product platform in the UK and the US. This collaboration aims to enhance the company's profile and sales in these regions, positioning Cellular Goods as a leading skincare brand on the platform. Looking ahead, Taylor expressed plans to continue expanding the 'Look Better' skincare range into new markets, focusing on revenue growth and increasing visibility among new and existing customers. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

November 27, 2023 06:53 AM Eastern Standard Time

Video

Women and Alzheimer’s Disease Subject of Giving Tuesday Webinar

Alzheimer’s Disease Research Foundation

Cure Alzheimer’s Fund will host Dr. Liisa Galea for a Giving Tuesday webinar on her research into women and Alzheimer’s disease. In this pre-recorded webinar, Dr. Galea presents her research on sex-based differences into the causes of Alzheimer's disease and discusses her findings with Meg Smith, CEO of Cure Alzheimer's Fund. Dr. Liisa Galea is the Treliving Family Chair in Women’s Mental Health at the Centre for Addiction and Mental Health (CAMH) in Toronto, Canada and a Professor of Psychiatry at the University of Toronto. Dr. Galea is a world-renowned expert in sex hormone influences on brain and behavior, with a focus on dementia and stress-related psychiatric disorders. Her research examines the intersection of hormones, and stress on brain plasticity in males and females. “Women develop Alzheimer's disease at twice the rate of men. Dr. Galea’s research into why women are more susceptible to Alzheimer’s and what is driving increased risk is impressive,” said CEO Smith. “She is a tireless advocate for women’s health research and for sex and gender-based analysis to improve cognitive aging for both women and men. We are lucky to hear from her.” “There is a lot of talk about precision medicine, the idea that we can tailor treatments based on our genes. But we rarely talk about how different treatments might be needed to combat neurodegenerative diseases like Alzheimer’s based on our sex,” said Galea. “The top three risk factors for late onset sporadic Alzheimer’s disease include APOE4 genotype and female sex. If you are an APOE4 carrier and a female you have an even greater risk of developing Alzheimer’s disease than if you are male carrier. Why not harness this information to see whether we can discover new therapies to combat this devastating illness. It’s time we figured out how sex plays a role, not only in the risk and progression of Alzheimer’s disease, but whether or not, different treatments may need to be tailored by sex.” For more information and to view the webinar, please visit Cure Alzheimer’s Fund at CureAlz.org and https://bit.ly/49jqQuO for the webinar. The webinar takes place during Alzheimer’s Awareness Month in November. It is estimated that more than 6.5 million Americans are currently living with Alzheimer’s disease two-thirds of those who are afflicted are women. It is projected that the share of adults 65 and older in the US population will rise to 22 percent by 2050. With age as the biggest risk factor, Alzheimer’s disease is poised to place an unmanageable financial burden on the US healthcare system, caregivers, and loved ones. About Cure Alzheimer’s Fund Cure Alzheimer’s Fund is a non-profit dedicated to funding the most promising research to prevent, slow, or reverse Alzheimer’s disease. Since its founding in 2004, Cure Alzheimer’s Fund has provided grants to the world’s leading researchers and contributed more than $180 million to research. Its funded initiatives have been responsible for many key breakthroughs in understanding the causes and pathology of Alzheimer’s disease. Cure Alzheimer’s Fund has received a 4-star rating for more than 12 consecutive years from Charity Navigator. With 100 percent of funds raised going to support research, Cure Alzheimer’s Fund has been able to provide grants to many of the best scientific minds in the field of Alzheimer’s research. For more information, visit https://www.curealz.org/. To learn about our the impact of Alzheimer’s on women and women working towards a cure, visit https://womenandalzheimers.org. Contact Details Barbara Chambers +1 978-417-9890 bchambers@curealz.org Company Website https://www.CureAlz.org

November 27, 2023 05:01 AM Eastern Standard Time

News Release

Renovaro Biosciences CEO unveils potential breakthrough therapies and AI partnerships for 2024

Renovaro Biosciences Inc

Renovaro Biosciences CEO Dr Mark Dybul joined Steve Darling from Proactive to share news about the significant progress the company is poised to make following the signing of a definitive agreement to merge with GEDiCube, a UK-based medical AI company renowned for its contributions to the early detection and remission of cancer, as well as expedited drug discovery. GEDiCube is set to rebrand as Renovaro.AI, and together, the entities are looking to hasten diagnosis processes, improve the efficacy of treatments, pioneer new therapies, and broaden the availability of vital technologies for cancer and other diseases. Dybul highlighted to Proactive that while Renovaro is currently concentrated on pancreatic cancer research, plans are afoot to extend their focus to include other solid tumors that are typically associated with a short life expectancy. These will be part of the first human Phase I/IIa studies anticipated to commence by mid-2024. He noted the potential of GEDi Cube’s AI technology to refine the focus of upcoming human trials on those cancers that are most amenable to treatment. Furthermore, the technology is expected to enrich the database of crucial markers for early diagnosis and tracking disease progression, thereby fostering the development of novel iterations of Renovaro’s treatment methodologies and the discovery of completely new therapeutic options. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

November 22, 2023 10:44 AM Eastern Standard Time

Video

News Release

Valeo Pharma announces new chief financial officer along with $2 million in cost reductions

Valeo Pharma Inc.

Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share details about recent executive changes within the company. Saviuk announced the appointment of Pascal Tougas as the new chief financial officer, succeeding Luc Mainville. Tougas is recognized as a well-experienced senior executive in the pharmaceutical industry, with a robust financial background. His previous tenure at Sanofi Canada for 11 years saw him in various key roles, including Country Head, Trade and Revenue Management, interim Chief Financial Officer Canada, and Director Controlling and Operations Canada, among others. Pascal is also well-qualified academically, holding a bachelor's degree in business administration from HEC Montreal along with a CPA designation. Additionally, Saviuk informed Proactive about Valeo Pharma’s strategic efforts aimed at reducing operational costs as the company advances towards profitability. One significant move in this direction is the realignment of the company’s organizational structure. This realignment is expected to yield cost savings while enhancing the efficiency and timeliness of decision-making within the company. These changes are projected to save the company over $2 million. Contact Details Proactive +1 347-449-0879 na-editorial@proactiveinvestors.com

November 21, 2023 07:41 AM Eastern Standard Time

Video

News Release

Tonix Pharmaceuticals' CEO reveals next-generation COVID vaccine technology chosen for key program

Tonix Pharmaceuticals

Tonix Pharmaceuticals CEO Dr Seth Lederman recently joined Steve Darling from Proactive to share exciting news about their COVID vaccine, TNX-1800, selected for testing in Project Next Gen, a White House initiative managed by the Department of Health and Human Services, NIH, and NIAID. The vaccine is based on a live virus platform, providing a unique approach to waking up the immune system. Live virus vaccines, like TNX-1800, offer more durable immunity that lasts a long time and can potentially block virus transmission, addressing limitations seen in mRNA vaccines. This choice of TNX-1800 is a testament to Tonix's nearly decade-long dedication to vaccine development. The technology platform can also be adapted to protect against other infectious diseases, such as monkeypox, smallpox, and tuberculosis, making it a versatile solution for future pandemics. This development highlights the significance of vaccine platforms for tackling various infectious threats. Tonix's approach promises to offer more robust, long-lasting immunity and potential transmission prevention, which could revolutionize our approach to infectious disease control. The platform's adaptability positions it as a valuable tool for future vaccine strategies. Contact Details Proactive Studio +1 347-449-0879 na-editorial@proactiveinvestors.com

November 20, 2023 01:57 PM Eastern Standard Time

Video

News Release

Tonix Pharmaceuticals finish Phase 3 trial of TNX-102 SL for management of Fibromyalgia

Tonix Pharmaceuticals

Tonix Pharmaceuticals CEO Dr Seth Lederman recently joined Steve Darling from Proactive to shed light on the latest developments in their research efforts. The company has successfully concluded the clinical phase of a Phase 3 registration-quality study for TNX-102 SL, a drug developed for the management of fibromyalgia. This study, which is double-blind and placebo-controlled, saw the enrollment of 457 patients across various sites in the United States. Lederman conveyed to Proactive that the topline results from this study are anticipated by late December. Should the results be favorable, this trial is expected to be the conclusive well-controlled efficacy trial needed for the submission of a New Drug Application to the U.S. Food and Drug Administration. The urgency and importance of this development are underscored by the fact that an estimated 6-12 million individuals in the US are afflicted with fibromyalgia, a condition that predominantly affects women. In addition to the TNX-102 study, Lederman also discussed another significant milestone: the enrollment of the first participant in a Phase 2 study, supported by the Department of Defense, focusing on TNX-1900 for the improvement of bone health in children with autism spectrum disorder. This investigator-initiated trial represents a foray into addressing the complex needs of children with autism, potentially offering a new therapeutic avenue to enhance their quality of life. Contact Details Proactive Studio +1 347-449-0879 na-editorial@proactiveinvestors.com

November 20, 2023 01:53 PM Eastern Standard Time

Video

Oxford Cannabinoid Technologies strengthens board with CMO Dr. Tim Corn

Oxford Cannabinoid Technologies Holdings PLC

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTC:OCTHF) CEO Clarissa Sowemimo Coker and CMO Dr Tim Corn speak to Thomas Warner from Proactive after the pharmaceutical group announced the appoint of Corn to its board of directors. The move follows his appointment as Chief Medical Officer in June 2023. Sowemimo-Coker highlights the importance of having a clinician on the board of a biopharmaceutical company. The appointment follows the successful announcement of Phase I single ascending dose results in October, reflecting OCT's commitment to addressing unmet medical needs with novel therapeutic approaches. Dr. Corn cites the combination of addressing unmet medical needs and the use of a novel cannabinoid approach as key factors that have attracted him to the business. He outlines his dual focus in the role, continuing as CMO to ensure efficient clinical programs aligned with regulatory requirements and bringing a physician's perspective to the board. He suggests that his expertise in clinical development and board work positions him well to balance patient interests and financial considerations. Discussing the company's cash runway, Sowemimo-Coker says the company is funded into April 2024. She assures stakeholders that the board is actively exploring various funding options, and updates will be provided as progress unfolds. While the details remain confidential, she hints at potential updates before the end of the year. The interview showcased OCT's commitment to advancing cannabinoid-based therapies, building a strong leadership team, and maintaining transparency in financial matters. Stakeholders are eagerly anticipating further developments as OCT continues its journey towards clinical and financial success. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

November 20, 2023 10:24 AM Eastern Standard Time

Video

AGC Biologics to Prepare Late Phase and Commercial Runs for Immunocore

AGC Biologics

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new late-stage clinical and process performance qualification (PPQ) project at its Heidelberg, Germany site with Immunocore Holdings Plc (Nasdaq: IMCR). Immunocore intends to use the Heidelberg site to complete late-stage manufacturing and prepare for commercialization for IMC-F106C, Immunocore’s PRAME-targeted bispecific therapy. Under the agreement, AGC Biologics will leverage its microbial fermentation and manufacturing experience to perform bench-scale qualification and process characterization, and other required studies to support phase III manufacturing, as well as PPQ runs. Pending a successful PPQ campaign and regulatory approvals, the Immunocore project is expected to move into commercial stages at the AGC Biologics Heidelberg site. This is the next step in the partnership for this candidate between the two companies, with AGC Biologics providing early-phase support for this same project. Immunocore and AGC Biologics previously worked together on commercial manufacturing readiness for KIMMTRAK® (tebentafusp-tebn) at the CDMO’s Copenhagen site. “This is a great example of the power of the AGC Biologics network and our ability to collaborate at our global sites to support important client projects,” said Dieter Kramer, General Manager, AGC Biologics Heidelberg. “I am extremely proud of our team here in Heidelberg and the work they’ve done to support this project. We are pleased Immunocore has agreed to work with us on these next important steps in their product’s lifecycle, as our team has the late-stage and commercial expertise to deliver what is needed.” AGC Biologics runs multiple cGMP microbial fermentation lines at its Heidelberg facility. The AGC Biologics Heidelberg site has produced biologics products for 40 years and has built a track record for navigating clients through the early clinical phases and into later stages to help prepare for commercial production. In addition to fermentation, the site serves as a center of excellence for plasmid DNA (pDNA) and messenger RNA (mRNA). To learn more about AGC Biologics’ microbial system-based biologics, plasmid DNA (pDNA) and messenger RNA (mRNA) manufacturing site in Heidelberg, visit www.agcbio.com/facilities/heidelberg. For more information on the company’s Protein Biologics, pDNA, Cell Therapy, Viral Vector and mRNA drug product services go to www.agcbio.com. About AGC Biologics AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 2,500 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is the partner of choice. To learn more, visit www.agcbio.com. Contact Details AGC Biologics Nick McDonald +1 425-419-3555 nmcdonald@agcbio.com

November 20, 2023 05:08 AM Eastern Standard Time

News Release

Breaking ground in vision restoration: Kiora Pharmaceuticals reveals promising results with KIO-301

Kiora Pharmaceuticals

Kiora Pharmaceuticals CEO Brian Strem joined Steve Darling from Proactive to share news the company's plan to broaden the clinical development of KIO-301, a treatment designed for various inherited retinal diseases. The expansion includes initiating a Phase 2 trial which will be controlled, double-masked, randomized, and will involve an ascending dose. This trial is set to include up to 20 patients suffering from Retinitis Pigmentosa (RP), who will receive doses monthly over a span of 90 days. Strem explained that this move is propelled by encouraging topline results from a Phase I/II clinical trial, which indicated that KIO-301 is a first-in-class small molecule with significant potential to improve vision for patients with RP, even those with extremely low vision or complete blindness. Moreover, Kiora Pharmaceuticals has plans to engage with the FDA in the fourth quarter of 2023. The goal of this meeting is to achieve consensus regarding the study designs, endpoints, and additional requirements necessary to conduct further studies in the United States and Europe. These studies would not only target RP but also extend to other inherited retinal diseases such as Choroideremia (CHM) and Stargardt disease. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

November 17, 2023 01:54 PM Eastern Standard Time

Video

1 ... 60 61 62 63 64 ... 250